Evidence map›Paper›PMID 30740414›Full record

ArticleAnnals of translational medicine2018

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Shih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai

Abstract readEditorialComment
In one paragraph

Article in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy.Journal of immunotherapy and precision oncology · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery.Molecular therapy. Nucleic acids · 2019
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Shih-Feng ChoLeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kenneth C AndersonLeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yu-Tzu TaiLeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Funding

Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0M
Role of Cytokines in Myeloma PathogenesisR01CA050947 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MITSIADES, CONSTANTINE S. · 1991 to 2018
$5.1M
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple MyelomaR01CA207237 · NCI · DANA-FARBER CANCER INST · PI ANDERSON, KENNETH C., CHAUHAN, DHARMINDER · 2016 to 2020
$2.0M
NCI NIH HHS P50 CA100707NCI NIH HHS R01 CA050947NCI NIH HHS R01 CA207237
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30740414
PMCPMC6330615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.